Physician profile
Hazel L Brooks
NPI 1255314498
$1,334.82
in general payments reported to CMS, 2019-2025
16 companies · $393 in 2025
The $393 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $95.41 · 2021: $92.27 · 2022: $94.07 · 2023: $220 · 2024: $306 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $919.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $411.70 | 2023-2025 | Azstarys |
| Glaxosmithkline, LLC. | $205.77 | 2019-2023 | Bexsero |
| Collegium Pharmaceutical, INC. | $147.26 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $119.13 | 2019-2024 | Jornay Pm |
| Sanofi Pasteur INC. | $107.17 | 2023-2025 | |
| Pfizer INC. | $69.77 | 2023-2025 | |
| Sobi, INC | $61.28 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.57 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $26.11 | 2021 | |
| Seqirus USA INC | $25.97 | 2025 | Flucelvax |
| Kyowa Kirin, INC. | $21.57 | 2023 | Crysvita |
| Neurelis, INC. | $19.36 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.95 | 2024 | |
| Tris Pharma INC | $17.85 | 2024 | Dyanavel Xr |
| Verrica Pharmaceuticals INC. | $14.64 | 2024 | Ycanth |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $11.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hazel Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.